Melnichenko V

Thieblemont C

Zinzani PL

English

Archivio istituzionale della ricerca - Alma Mater Studiorum Università di Bologna

ErratumZinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primarymediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141-145.DownloadePage 144, left column, lines 2 and 3 of the main text: The sentence “Four patients (7.5%) discontinued treatment because oftreatment-related AE” should read “Four patients (7.5%) interrupted treatment because of treatment-related AE.”https://doi.org/10.1182/blood.2024024192© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0),permitting only noncommercial, nonderivative use with attribution. All other rights reserved.1316 28 MARCH 2024 | VOLUME 143, NUMBER 13d from http://ashpublications.org/blood/article-pdf/143/13/1316/2218711/blood_bld-2024-024192-main.pdf by guest on 27 June 2024

Erratum:Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141-145.

https://cris.unibo.it/bitstream/11585/969790/2/blood_bld-2024-024192-main.pdf

Erratum:Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141-145.

Abstract

Similar works

Full text

Available Versions

Archivio istituzionale della ricerca - Alma Mater Studiorum Università di Bologna